[Asia Economy Reporter Lee Gwan-ju] Myongji Hospital, the first in Korea to open a 'COVID-19 Sequelae Clinic,' will hold its second symposium to diagnose the actual conditions of sequelae and examine future prospects.
Myongji Hospital announced on the 20th that it will hold the 'COVID-19 Sequelae Treatment Clinical Symposium Season 2' on the 22nd, marking one year since the Omicron surge.
At this symposium, based on clinical experiences and statistics of patients who have visited the clinic since it opened in March last year as Korea's first COVID-19 sequelae clinic, the symptoms of sequelae will be analyzed, and opinions on treatment experiences and future medical directions will be presented.
The Myongji Hospital COVID-19 Sequelae Clinic, which has focused on sequelae treatment through multidisciplinary care involving 14 departments, has treated over 3,800 patients so far. In particular, by analyzing accumulated clinical data, it announced that "65% of patients complain of three or more complex symptoms," and has concentrated on identifying 'Long COVID' by publishing research on symptoms by sequelae duration in the SCI journal, the Journal of the Korean Medical Science (JKMS).
The symposium will be conducted in two sessions under the moderation of Professor Ha Eun-hye of the Department of Pulmonology, who leads the sequelae clinic: ▲ Clinical research results of Myongji Hospital COVID-19 Sequelae Clinic ▲ Prospects of COVID-19 sequelae. Hospital Director Kim Jin-gu said, "This symposium will be a meaningful occasion to present the clinical research results accumulated over the past year based on the experience and expertise gained from operating the COVID-19 sequelae clinic and to share the latest insights on the prospects of COVID-19 sequelae."
Following the first symposium held in April last year titled 'It’s Not Over Until It’s Over ? COVID-19 Sequelae Clinical Symposium,' this second symposium will be held on the 22nd at 2 p.m. in the Nongcheon Hall of Myongji Hospital’s main auditorium, with on-site attendance and live streaming via YouTube.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.



